Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
256
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 183 more
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Conditions
HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Other · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Interventions
Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography, Trastuzumab, Trastuzumab Deruxtecan
Other · Procedure · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
Interventions
methotrexate, liposomal cytarabine, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Terminated Phase 2 Interventional Results available

Brain Metastases In ErbB2-Positive Breast Cancer

NCT00437073
Conditions
Neoplasms, Breast
Interventions
capecitabine, topotecan, lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more
Conditions
Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions
BKM120, Trastuzumab, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more
Conditions
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the Pancreas, Colorectal Cancer, Colorectal Carcinoma, Renal Cancer, Kidney Cancer, Cancer of the Kidney, Cancer of Kidney, Ovarian Cancer, Ovary Cancer, Cancer of the Ovary, Cancer of Ovary
Interventions
MEDI4736
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Kidney Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8
Interventions
Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Results available

TPI 287 in Breast Cancer Metastatic to the Brain

NCT01332630
Conditions
Breast Cancer
Interventions
TPI 287, Dexamethasone, Benadryl, Ranitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, Tucatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 15 more
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
798
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
Interventions
Best Practice, Ketoconazole
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Sacituzumab Govitecan
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
296
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 210 more
Conditions
Brain Cancer Metastatic, CMV Viremia
Interventions
Valganciclovir
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland